Marco Garrido-Cumbrera1, Victoria Navarro-Compán2, Pedro Zarco3, Eduardo Collantes-Estévez4, David Gálvez-Ruiz5, Olta Braçe5, Jorge Chacón García5, Carles Blanch Mur6, Angels Costa Ferrer6, Alvaro Hidalgo Vega7, Pedro Plazuelo Ramos8, Jordi Gratacós Masmitja9. 1. Health & Territory Research, Universidad de Sevilla, Seville, Spain; Spanish Coordinator of Associations of Spondylarthritis (CEADE), Madrid, Spain. Electronic address: mcumbrera@us.es. 2. Department of Rheumatology, University Hospital La Paz, IdiPaz. Madrid, Spain. 3. Department of Rheumatology, Foundation Hospital of Alcorcón, Madrid, Spain. 4. Department of Rheumatology, Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain. 5. Health & Territory Research, Universidad de Sevilla, Seville, Spain. 6. Novartis, Barcelona, Spain. 7. Universidad de Castilla-La Mancha, Toledo, Spain. 8. Spanish Coordinator of Associations of Spondylarthritis (CEADE), Madrid, Spain. 9. Department of Rheumatology, Hospital Universitari Parc Taulí, Sabadell, I3PT, UAB, Spain.
Abstract
OBJECTIVE: Atlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach. METHODS: The Atlas 2017 based its results on an extensive cross-sectional patient survey conducted in Spain (2016), validated by a multidisciplinary group of experts on spondyloarthritis. RESULTS: Data from 680 patients with axSpA were obtained, most of them suffered from AS, were HLA-B27 positive, older than 45 years, and live as part of a couple. A large percentage had university studies, were disabled and members of a patient association. Patients reported a diagnostic delay of 8.5 years, high disease activity (BASDAI 5.5±2.2), moderate-important stiffness (61.0%), medium-high functional limitation (74.9%), and psychological distress (GHQ 5.7±4.5). A total of 54.7% reported taking NSAIDs, 28.4% DMARDs, 36.3% biological therapy and 32.2% were not receiving pharmacological treatment. CONCLUSIONS: The Atlas survey data reveals still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated.
OBJECTIVE:Atlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach. METHODS: The Atlas 2017 based its results on an extensive cross-sectional patient survey conducted in Spain (2016), validated by a multidisciplinary group of experts on spondyloarthritis. RESULTS: Data from 680 patients with axSpA were obtained, most of them suffered from AS, were HLA-B27 positive, older than 45 years, and live as part of a couple. A large percentage had university studies, were disabled and members of a patient association. Patients reported a diagnostic delay of 8.5 years, high disease activity (BASDAI 5.5±2.2), moderate-important stiffness (61.0%), medium-high functional limitation (74.9%), and psychological distress (GHQ 5.7±4.5). A total of 54.7% reported taking NSAIDs, 28.4% DMARDs, 36.3% biological therapy and 32.2% were not receiving pharmacological treatment. CONCLUSIONS: The Atlas survey data reveals still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated.
Keywords:
Axial spondyloarthritis; Burden of disease; Carga de la enfermedad; Espondiloartritis axial; Gestión de la atención sanitaria; Healthcare management; Patient perspective; Perspectiva del paciente
Authors: Marco Garrido-Cumbrera; David Gálvez-Ruiz; Carlos J Delgado-Domínguez; Denis Poddubnyy; Victoria Navarro-Compán; Laura Christen; Raj Mahapatra; Souzi Makri; Christine Bundy Journal: RMD Open Date: 2021-11
Authors: Marco Garrido-Cumbrera; Christine Bundy; Victoria Navarro-Compán; Souzi Makri; Sergio Sanz-Gómez; Laura Christen; Raj Mahapatra; Carlos J Delgado-Domínguez; Denis Poddubnyy Journal: Arthritis Care Res (Hoboken) Date: 2021-12 Impact factor: 5.178